BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22495372)

  • 1. Assessment of human epidermal growth factor receptor 2 status in urothelial carcinoma of the upper urinary tract: a study using dual-color in situ hybridization and immunohistochemistry.
    Vershasselt-Crinquette M; Colin P; Ouzzane A; Gnemmi V; Robin YM; Aubert S; Villers A; Leroy X
    Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):363-6. PubMed ID: 22495372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patients.
    Sasaki Y; Sasaki T; Kawai T; Morikawa T; Matsusaka K; Kunita A; Kume H; Aoki I; Homma Y; Fukayama M
    Int J Clin Exp Pathol; 2014; 7(2):699-708. PubMed ID: 24551292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization.
    Wang X; MacLennan GT; Zhang S; Montironi R; Lopez-Beltran A; Tan PH; Foster S; Baldridge LA; Cheng L
    Hum Pathol; 2009 Feb; 40(2):211-7. PubMed ID: 18799188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas.
    Aumayr K; Klatte T; Neudert B; Birner P; Shariat S; Schmidinger M; Susani M; Haitel A
    Pathol Oncol Res; 2018 Jul; 24(3):575-581. PubMed ID: 28755093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma.
    Behzatoğlu K; Yörükoğlu K; Demir H; Bal N
    Eur Urol Focus; 2018 Apr; 4(3):399-404. PubMed ID: 28753766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In situ analysis of HER2 mRNA in gastric carcinoma: comparison with fluorescence in situ hybridization, dual-color silver in situ hybridization, and immunohistochemistry.
    Kim MA; Jung JE; Lee HE; Yang HK; Kim WH
    Hum Pathol; 2013 Apr; 44(4):487-94. PubMed ID: 23084583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression.
    Chen PC; Yu HJ; Chang YH; Pan CC
    J Clin Pathol; 2013 Feb; 66(2):113-9. PubMed ID: 23087329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK; Tjan S; Parkes RK; O'Malley FP
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
    Lim SJ; Cantillep A; Carpenter PM
    Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
    Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
    Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques.
    Nedjadi T; Al-Maghrabi J; Assidi M; Dallol A; Al-Kattabi H; Chaudhary A; Al-Sayyad A; Al-Ammari A; Abuzenadah A; Buhmeida A; Al-Qahtani M
    BMC Cancer; 2016 Aug; 16():653. PubMed ID: 27539085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 protein overexpression and gene amplification in upper urinary tract transitional cell carcinoma: systematic analysis applying tissue microarray technique.
    Langner C; Gross C; Rehak P; Ratschek M; Rüschoff J; Zigeuner R
    Urology; 2005 Jan; 65(1):176-80. PubMed ID: 15667899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 gene amplification and protein expression in pancreatic ductal adenocarcinomas.
    Aumayr K; Soleiman A; Sahora K; Schindl M; Werba G; Schoppmann SF; Birner P
    Appl Immunohistochem Mol Morphol; 2014; 22(2):146-52. PubMed ID: 23702645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization.
    Im SA; Kim JW; Kim JS; Kim MA; Jordan B; Pickl M; Han SW; Oh DY; Lee HJ; Kim TY; Kim WH; Yang HK; Bang YJ
    Diagn Mol Pathol; 2011 Jun; 20(2):94-100. PubMed ID: 21532492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract.
    Ohtsuka Y; Kawakami S; Fujii Y; Koga F; Saito K; Ando N; Takizawa T; Kageyama Y; Kihara K
    BJU Int; 2006 Jun; 97(6):1322-6. PubMed ID: 16686732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience.
    Rizzo A; Mollica V; Giunchi F; Dall'Olio FG; Rosellini M; Marchetti A; Franceschini T; Schiavina R; Brunocilla E; Fiorentino M; Ardizzoni A; Massari F
    Pathol Res Pract; 2021 Apr; 220():153410. PubMed ID: 33765474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of Her2/neu overexpression in urothelial carcinomas.
    Alexa A; Baderca F; Zăhoi DE; Lighezan R; Izvernariu D; Raica M
    Rom J Morphol Embryol; 2010; 51(2):277-82. PubMed ID: 20495743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder.
    Kim B; Kim G; Song B; Lee C; Park JH; Moon KC
    Dis Markers; 2016; 2016():8463731. PubMed ID: 27034533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
    Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
    Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rsf-1/HBXAP overexpression is independent of gene amplification and is associated with poor outcome in patients with urinary bladder urothelial carcinoma.
    Liang PI; Wu LC; Sheu JJ; Wu TF; Shen KH; Wang YH; Wu WR; Shiue YL; Huang HY; Hsu HP; Chen YH; Chen LT; Li CF; Liao AC
    J Clin Pathol; 2012 Sep; 65(9):802-7. PubMed ID: 22685262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.